NCT02117297View on ClinicalTrials.gov

SCT Plus Immune Therapy in Average Risk AML/MDS

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 12, 2012

Primary Completion Date

March 30, 2023

Study Completion Date

March 30, 2023

Conditions
Acute Myelogenous LeukemiaMyelodysplastic Syndrome
Interventions
DRUG

Gemtuzumab Ozogamicin

Gemtuzumab, 9.0 mg/m2, will be given IV over 2 hours two times post allogeneic transplantation.

Trial Locations (1)

10595

New York Medical College, Valhalla

Sponsors
All Listed Sponsors
lead

New York Medical College

OTHER

NCT02117297 - SCT Plus Immune Therapy in Average Risk AML/MDS | Biotech Hunter | Biotech Hunter